Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Change in Accured Expenses (2020 - 2026)

Longeveron (LGVN) posted quarterly Change in Accured Expenses of $293000.0 for Q1 2026, up 270.35% year-over-year from $79114.6 in Q1 2025, and down 76.47% quarter-over-quarter from $1.2 million in Q4 2025.

Longeveron (LGVN) Change in Accured Expenses (2020 - 2026) Analysis & Trends

Longeveron's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at $293000.0 for Q1 2026.

  • In Q1 2026, Change in Accured Expenses rose 270.35% year-over-year to $293000.0; the TTM figure through Mar 2026 stood at $1.8 million (up 1228.21% YoY), while the FY2025 annual figure was $1.3 million, up 388.68% from the prior year.
  • Change in Accured Expenses for Q1 2026 stood at $293000.0, down from $1.2 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $1.2 million in Q4 2025, with the low at -$604000.0 in Q1 2022.
  • The 5-year median for Change in Accured Expenses is $66000.0 (2024), against an average of $157529.4.
  • Peak annual rise in Change in Accured Expenses reached 1786.36% in 2025, while the deepest fall reached 375.76% in 2025.
  • Longeveron's Change in Accured Expenses stood at -$78000.0 in 2022, then soared by 970.51% to $679000.0 in 2023, then tumbled by 90.28% to $66000.0 in 2024, then soared by 1786.36% to $1.2 million in 2025, then tumbled by 76.47% to $293000.0 in 2026.
  • Business Quant data shows LGVN's Change in Accured Expenses at $293000.0 in Q1 2026, $1.2 million in Q4 2025, and -$182000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 11.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 212.44 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 61.62 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 68.82 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00 -

Historic Data

Download Data
DateValue
Mar 31, 2026 293,000.00
Mar 31, 2026 293,000.00
Dec 31, 2025 1.25 Mn
Dec 31, 2025 1.25 Mn
Sep 30, 2025 -182,000.00
Sep 30, 2025 -182,000.00
Jun 30, 2025 404,000.00
Jun 30, 2025 404,000.00
Mar 31, 2025 -172,000.00
Mar 31, 2025 -172,000.00
Dec 31, 2024 66,000.00
Dec 31, 2024 66,000.00
Sep 30, 2024 66,000.00
Sep 30, 2024 66,000.00
Jun 30, 2024 -116,000.00
Jun 30, 2024 -116,000.00
Mar 31, 2024 249,000.00
Mar 31, 2024 249,000.00
Dec 31, 2023 679,000.00
Dec 31, 2023 679,000.00